Zhu Y, Moriarty JP, Swanson KM, et al. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet Med. 2021;23:461–70.

Article  PubMed  CAS  Google Scholar 

Chan SH, Bylstra Y, Teo JX, et al. Analysis of clinically relevant variants from ancestrally diverse Asian genomes. Nat Commun. 2022;13:6694.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chan SL, Ang X, Sani LL, et al. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. Br J Clin Pharmacol. 2016;82:1636–46.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mosch R, van der Lee M, Guchelaar HJ, et al. Pharmacogenetic panel testing: a review of current practice and potential for clinical implementation. Annu Rev Pharmacol Toxicol. 2024.

Genes-Drugs. US Department of Health & Human Services (HHS): Clinical Pharmacogenetics Implementation Consortium, 2020.

Guidelines. USA: Clinical Pharmacogenetics Implementation Consortium. 2024.

Pereira NL, Cresci S, Angiolillo DJ, et al. CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association. Circulation. 2024;150:e129–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chan SL, Ng HY, Sung C, et al. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. Pharmacogenomics J. 2019;19:401–10.

Article  PubMed  CAS  Google Scholar 

Schildcrout JS, Denny JC, Roden DM. On the potential of preemptive genotyping towards preventing medication-related adverse events: results from the South Korean National Health Insurance Database. Drug Saf. 2017;40:1–2.

Article  PubMed  PubMed Central  Google Scholar 

Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014;89:25–33.

Article  PubMed  PubMed Central  Google Scholar 

Hart MR, Garrison LP Jr., Doyle DL, et al. Projected cost-effectiveness for 2 gene-drug pairs using a multigene panel for patients undergoing percutaneous coronary intervention. Value Health. 2019;22:1231–9.

Article  PubMed  Google Scholar 

Shi Y, Graves JA, Garbett SP, et al. A decision-theoretic approach to panel-based, preemptive genotyping. MDM Policy Pract. 2019;4:2381468319864337.

Article  PubMed  PubMed Central  Google Scholar 

Morris SA, Alsaidi AT, Verbyla A, et al. Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin Pharmacol Ther. 2022;112:1318–28.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89:464–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110:563–72.

Article  PubMed  PubMed Central  Google Scholar 

Elaine Ah gi Lo LXM, Wee HL, Su-Yin DT, Yan B, Tan KML, Aminkeng F, Yuan NK, Shyong Tai E, Goh BC. Selection and prioritization of clinically actionable drug-gene pairs for a pre-emptive pharmacogenomics service in hospitals and primary care settings in Singapore. Pharmacogenom Glob Res Netw. 2021.

Ng FFJ, Verma R, Sani L, et al. A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study). Pharmacogenomics J. 2025;25:7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tan J. Citizens, PRs aged 40 to 59 can enrol for Healthier SG programme. In: The straits times. Singapore: SPH Media Limited, Co., 2023.

Loy EY, Molinar D, Chow KY, et al. National breast cancer screening programme, Singapore: evaluation of participation and performance indicators. J Med Screen. 2015;22:194–200.

Article  PubMed  Google Scholar 

Drug and Vaccine Evaluation Methods and Process Guide. 3.1 ed. Republic of Singapore: Agency for Care Effectiveness. 2023.

Wong XY, Chng WJ, Aziz MIA, et al. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2022;22:207–15.

Article  PubMed  Google Scholar 

Caro JJ. Discretely integrated condition event (DICE) simulation for pharmacoeconomics. Pharmacoeconomics. 2016;34:665–72.

Article  PubMed  Google Scholar 

Delivering a transparent and flexible approach to health economic models. PPD Evidera 2025.

Caro JJ, Maconachie R, Woods M, et al. Leveraging DICE (Discretely-Integrated Condition Event) simulation to simplify the design and implementation of hybrid models. Value Health. 2020;23:1049–55.

Article  PubMed  Google Scholar 

Lee CR, Luzum JA, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112:959–67.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J. 2015;169:899-905.e1.

Article  PubMed  CAS  Google Scholar 

Zhang S, Wang W, Sawhney JPS, et al. Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia. Int J Cardiol. 2020;310:16–22.

Article  PubMed  Google Scholar 

Timmers L, Swart EL, Boons CC, et al. The use of capecitabine in daily practice: a study on adherence and patients’ experiences. Patient Prefer Adherence. 2012;6:741–8.

Article  PubMed  PubMed Central  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology Colon Cancer. Version 4.2025 ed: National Comprehensive Cancer Network, 2025.

Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19:1459–67.

Article  PubMed  CAS  Google Scholar 

Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gout—achieving the management goal. Republic of Singapore: Agency for Care Effectiveness, 2023.

Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359:789–99.

Article  PubMed  CAS  Google Scholar 

Prices and Price Indices. Republic of Singapore: Department of Statistics, 2024.

Ghabri S, Dawoud D, Drummond M. Methods for including adverse events in economic evaluations: suggestions for improvement. Value Health. 2024;27:936–42.

Article  PubMed  Google Scholar 

Bishai D, Brenzel L, Padula WV. 383 Making models probabilistic and estimating the value of information. In: Handbook of applied health economics in vaccines. Oxford University Press; 2023.

Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021. https://doi.org/10.1002/cpt.2149.

Article  PubMed  PubMed Central  Google Scholar 

Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98:19–24.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mulder TAM, de With M, del Re M, et al. Clinical CYP2D6 genotyping to personalize adjuvant tamoxifen treatment in ER-positive breast cancer patients: current status of a controversy. Cancers. 2021. https://doi.org/10.3390/cancers13040771.

Article